Remimazolam on the Incidence of Postoperative Acute Kidney Injury

Seoul National University

Status

Not yet enrolling

Conditions

Remimazolam

Fluid Therapy

Propofol

Acute Kidney Injury

Fluid Therapy DURING SURGERY

Hepatobiliary Surgery

Hemodynamic Stability

Treatments

Drug: Remimazolam (Byfavo)

Drug: propofol

Study type

Interventional

Funder types

Other

Identifiers

NCT07674719

B-2509-996-004

Details and patient eligibility

About

We hypothesized that in patients undergoing elective hepatobiliary-pancreatic surgery, the group in which anesthesia is induced and maintained with remimazolam during surgery would maintain hemodynamic stability and reduce the incidence of postoperative acute kidney injury compared to propofol. The purpose is to provide practical evidence for perioperative management differentiated from other surgeries for hepatobiliary-pancreatic surgery patients for whom intraoperative fluid therapy is restricted.

Enrollment

78 estimated patients

Sex

All

Ages

19 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Ages 19 or older and under 85
Patients scheduled to undergo elective hepatopancreatic surgery under general anesthesia
American Society of Anesthesiologists (ASA) physical grade 1-3
Those who voluntarily consented to a written informed consent form prior to participation in the study

Exclusion criteria

Patients with hypersensitivity to other benzodiazepine drugs, including remimazolam, and to the components of this drug (e.g., patients with severe hypersensitivity to dextran 40)
Patients with hypersensitivity to propofol
Patients with underlying conditions: liver, neurological disorders, or acute narrow-angle glaucoma
Patients with severe or acute respiratory failure
Patients in shock or a coma
Patients taking TCA antidepressants
Patients with preoperative chronic kidney disease